China National Accord Medicines Corporation Ltd.
The Third Quarterly Report for 2019
October 2019
Section I. Important Notice
Board of Directors Supervisory Committee all directors supervisors and senior
executives of China National Accord Medicines Corporation Ltd. (hereinafter
referred to as the Company) hereby confirm that there are no any fictitious
statements misleading statements or important omissions carried in this report
and shall take all responsibilities individual and/or joint for the reality
accuracy and completion of the whole contents.
All directors are present the meeting of the Board for deliberating the Third
Quarter Report of the Company in person.Lin Zhaoxiong person in charge of the Company head of the accounting works
Wei Pingxiao and Wang Ying accounting body principals (accountant in charge)
hereby confirm that the Financial Report of the Third Quarterly Report is
authentic accurate and complete.Section II. Basic information of Company
I. Main accounting data and financial indexes
Whether it has retroactive adjustment or re-statement on previous accounting data or not
□ Yes √ No
Current period-end Period-end of last year Increase/decrease
Total assets (RMB) 34816993187.67 28930300519.97 20.35%
Net assets attributable to
shareholders of listed company
(RMB)
12451750624.00 11618432603.28 7.17%
Current period
Increase/decrease in
comparison with same
period of last year
Year-begin to end of
the Period
Increase/decrease in
comparison with
year-begin to
period-end of last year
Operating revenue (RMB) 13647793431.64 24.21% 38875940809.07 22.38%
Net profit attributable to
shareholders of the listed company
(RMB)
311310706.52 9.14% 962144066.92 3.79%
Net profit attributable to
shareholders of the listed company
after deducting non-recurring gains
and losses (RMB)
303365280.52 7.45% 943065728.47 4.14%
Net cash flow arising from
operating activities (RMB)
-- -- 1072962161.22 90.24%
Basic earnings per share
(RMB/Share)
0.735 10.36% 2.247 3.79%
Diluted earnings per share
(RMB/Share)
0.735 10.36% 2.247 3.79%
Weighted average ROE 2.53%
0.09 percentage points
decline
7.94%
1.27 percentage points
decline
Note: the weighted average ROE has 0.09 percentage points down from same period last year and 1.27 percentage points down at
year-begin to period-end over same period last year mainly because a strategy investor was introduced by Guoda Drugstore in
second half of last year.Items and amount of extraordinary profit (gains)/losses
√Applicable □Not applicable
In RMB
Item
Amount from year-begin to
end of the Period
Note
Gains/losses from the disposal of non-current asset (including the
write-off that accrued for impairment of assets)
487779.48
Governmental subsidy reckoned into current gains/losses (not
including the subsidy enjoyed in quota or ration according to
national standards which are closely relevant to enterprise’s
business)
29325892.83
Received vary taxes subsidies
and financial rewards in the
period
Reversal of impairment reserve for account receivable with
separate impairment testing
1216744.26
Net gain/loss of impairment
provision switch-back for
receivables
Gains/losses on entrusted loans 2563975.31
The gains obtained from offering
entrust loans to China National
Zhijun (Suzhou)
Other non-operating income and expenditure except for the
aforementioned items
2455770.91
Other gains/losses satisfy a definition of extraordinary
gains/losses
22424.73
Less: impact on income tax 8393659.91
Impact on minority shareholders’ equity (post-tax) 8600589.16
Total 19078338.45 --
Concerning the extraordinary profit (gain)/loss defined by Q&A Announcement No.1 on Information Disclosure for Companies
Offering Their Securities to the Public --- Extraordinary Profit/loss and the items defined as recurring profit (gain)/loss according to
the lists of extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their
Securities to the Public --- Extraordinary Profit/loss explain reasons
□ Applicable √ Not applicable
In reporting period the Company has no particular about items defined as recurring profit (gain)/loss according to the lists of
extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to
the Public --- Extraordinary Profit/loss.II. Statement of the total shareholders and shares-held of top ten shareholders at end of the
Period
1. Total number of common shareholders at the end of this report period and top ten common shareholders
In Share
Total common shareholders at the
end of report period 21620
Total preference shareholders
with voting rights recovered at
end of reporting period (if
applicable)
0
Top ten shareholders
Shareholders
Nature of
shareholder
Proportion of
shares held
Amount of shares
held
Amount of
restricted shares
held
Number of share pledged/frozen
State of share Amount
Sinopharm Group
Co. Ltd.
State-owned
corporate
56.06% 239999991 55057700
Hong Kong
Securities
Clearing
Company Ltd
Overseas
corporate 4.48% 19163870
HTHK/CMG
FSGUFP-CMG
FIRST STATE
CHINA
GROWTH FD
Overseas
corporate 2.68% 11469644
China National
Pharmaceutical
Foreign Trade
Corp.
State-owned
corporate
1.24% 5323043 5323043
Fidelity
Investment
Management
(Hong Kong)
Limited - Client’s
fund
Overseas
corporate 1.13% 4825907
# Beijing
Haoqing Fortune
Investment
Management Co.Ltd. – Haoqing
Value Stable No.8
Investment Fund
Domestic non
state-owned
corporate
0.96% 4118716
Basic endowment
insurance fund-
portfolio 1003
Domestic non
state-owned
corporate
0.95% 4080913
Central Huijin
Investment Ltd.State-owned
corporate 0.89% 3804400
Bank of China -
Harvest Health
Care Stock
Securities
Domestic non
state-owned
corporate
0.76% 3258525
Investment Funds
BBH BOS S/A
FIDELITY FD -
CHINA FOCUS
FD
Overseas
corporate 0.76% 3246061
Particular about top ten shareholders with un-restrict shares held
Shareholders Amount of un-restrict shares held
Type of shares
Type Amount
Sinopharm Group Co. Ltd. 184942291
RMB ordinary
shares
184942291
Hong Kong Securities Clearing
Company Ltd 19163870
RMB ordinary
shares
19163870
HTHK/CMG FSGUFP-CMG FIRST
STATE CHINAGROWTH FD
11469644
Domestically
listed foreign
shares
11469644
China National Pharmaceutical
Foreign Trade Corp.
5323043
RMB ordinary
shares
5323043
Fidelity Investment Management
(Hong Kong) Limited - Client’s fund
4825907
RMB ordinary
shares
4825907
# Beijing Haoqing Fortune
Investment Management Co. Ltd. –
Haoqing Value Stable No.8
Investment Fund
4118716
RMB ordinary
shares
4118716
Basic endowment insurance fund-
portfolio 1003
4080913
RMB ordinary
shares
4080913
Central Huijin Investment Ltd. 3804400
RMB ordinary
shares
3804400
Bank of China - Harvest Health Care
Stock Securities Investment Funds
3258525
RMB ordinary
shares
3258525
BBH BOS S/A FIDELITY FD -
CHINA FOCUS FD
3246061
Domestically
listed foreign
shares
3246061
Explanation on associated
relationship among the aforesaid
shareholders
It is unknown that there exists no associated relationship or belongs to the consistent actionist
among the other tradable shareholders regulated by the Management Measure of Information
Disclosure on Change of Shareholding for Listed Companies.
Explanation on top ten common
shareholders involving margin
business (if applicable)
Beijing Hao Qing Wealth Investment Management Co. Ltd. –Hao Qing Value Stable No.8
Investment Fund holds 4048216 shares of the Company through margin trading and
refinancing secured security account
Whether top ten common shareholders or top ten common shareholders with un-restrict shares held have a buy-back agreement
dealing in reporting period
□ Yes √ No
The shareholders of the Company have no buy-back agreement dealing in reporting period.
2. Total of shareholders with preferred stock held and the top ten shareholdings
□Applicable √Not applicable
Section III. Important events
I. Particular about major changes from items of main accounting statements and financial
indexes as well as reasons
√ Applicable □Not applicable
1. Note receivable: decreased 772 million Yuan over that of period-begin with growth rate of -56.88% mainly because according to
the presentation requirements of statement at end of the period the bank acceptance bill in note receivable was listed under the item
of “Receivable financing”;
2. Accounts receivable: increased 3844 million Yuan over that of period-begin with growth rate of 41.17% mainly because volume
of business increased in the period account receivable goes up and payment collection period increased at the same time;
3. Receivable financing: increased 400 million Yuan over that of period-begin mainly because according to the presentationrequirements of statement at end of the period the bank acceptance bill in note receivable was listed under the item of “Receivablefinancing”;
4. Interest receivable: increased 6.1777 million Yuan over that of period-begin with growth rate of 75.12% mainly because the
deposit interest increased;
5. Right-of-use assets: increased 1860 million Yuan over that of period-begin mainly due to the implementation of new leasing
standards in the period;
6. Total non-current assets: increased 2114 million Yuan over that of period-begin with growth rate of 47.66% mainly because the
right-of-use assets increased for new leasing standards implemented in the period;
7. Accounts payable: increased 2678 million Yuan over that of period-begin with growth rate of 41.41% mainly because volume of
business increased in the period purchase volume and account payable increase accordingly;
8. Dividends payable: increased 4.7064 million Yuan over that of period-begin with growth rate of 73.66% mainly because the
accrual of bonus of minority shareholders payable increased;
9. Non-current liabilities due within one year: increased 533 million Yuan over that of period-begin with growth rate of 9093.11%
mainly due to the implementation of new leasing standards in the period the ending book value of leasing liabilities due for
repayment within one year from the balance sheet date was listed under the item of “Non-current liabilities due within one year”;
10. Other current liabilities: increased 330700 Yuan over that of period-begin with growth rate of 113.07% mainly because the
output tax amount ready for transfer increased over that of period-begin;
11. Long-term borrowings: decreased 31.60 million Yuan over that of period-begin with growth rate of -100.00% mainly because
the long-term loan was re-classified to non-current liability due within one year;
12. Lease liabilities: increased 1165 million Yuan over that of period-begin mainly due to the implementation of new leasing
standards in the period;
13. Long-term payables: decreased 3.764 million Yuan over that of period-begin with growth rate of -82.47% mainly due to the
implementation of new leasing standards in the period the finance lease before the first execution date was adjusted to lease
liabilities;
14. Total non-current liabilities: increased 1126 million Yuan over that of period-begin with growth rate of 422.45% mainly because
lease liabilities increased for the implementation of new leasing standards in the period;
15. Total liabilities: increased 4875 million Yuan over that of period-begin with growth rate of 32.44% mainly because volume of
business increased in the period purchase volume and account payable increase accordingly;
16. Operating revenue: increased 7109 million Yuan on a y-o-y basis with growth rate of 22.38% mainly because business income
increased for the good business performance in the period;
17. Operating costs: increased 6552 million Yuan on a y-o-y basis with growth rate of 23.30% mainly because business income
increased for the good business performance in the period business cost increased correspondingly;
18. Finance costs: increased 69.5683 million Yuan on a y-o-y basis with growth rate of 88.87% mainly due to the implementation of
new leasing standards in the period during the lease terms interest expenses shall be calculated according to the discount rate for
lease liabilities there was no such item in the same period last year;
19. Other incomes: increased 14.7031 million Yuan on a y-o-y basis with growth rate of 118.53% mainly because fiscal subsidy
received in period increased;
20. Impairment losses on financial assets: increased 15.1252 million Yuan on a y-o-y basis with growth rate of 3156.28% mainly
because the account receivable has increased over same period last year at end of the period than the bad debt provision accrual in
the period increased on a y-o-y basis;
21. Impairment losses: increased 714900 Yuan on a y-o-y basis with growth rate of 613.43% mainly because reversal of the
inventory falling price reserves declined from a year earlier;
22. Gain on disposal of assets: decreased 3.7735 million Yuan on a y-o-y basis with growth rate of -86.59% mainly because at same
period last year there was a property funds collected by the government was received by the Company while no such item in the
period;
23. Minority shareholders’ gains and losses: increased 81.7569 million Yuan on a y-o-y basis with growth rate of 97.93% mainly
because at second half of 2018 subsidiary Guoda Drugstore introduced a strategy investor the gains/losses of minority shareholders
increased on a y-o-y basis in the period;
24. Total comprehensive income attributable to minority shareholders: increased 81.7569 million Yuan on a y-o-y basis with growth
rate of 97.93% mainly because at second half of 2018 subsidiary Guoda Drugstore introduced a strategy investor the total
comprehensive income attributable to minority shareholders increased correspondingly;
25. Tax refunds: increased 1.7933 million Yuan on a y-o-y basis with growth rate of 104.58% mainly because the tax refund
increased compared with same period of last year;
26. Cash payments related to other operating activities: decreased 484 million Yuan on a y-o-y basis with growth rate of -38.77%
mainly due to the implementation of new leasing standards in the period the rents paid in the period are reckoned into cash paid with
other financing activity concerned while no such item at same period lat year;
27. Net cash flows from operating activities: increased 509 million Yuan on a y-o-y basis with growth rate of 90.24% mainly due to
the good operation performance cash received for goods sales and providing services increased correspondingly; and due to the
implementation of new leasing standards in the period the rents paid in the period are reckoned into cash paid with other financing
activity concerned while no such item at same period lat year;
28. Cash received from returns on investments: decreased 52.7204 million Yuan on a y-o-y basis with growth rate of -40.26%
mainly because the investment dividend received from joint venture declined on a y-o-y basis;
29. Cash received with other investing activities: decreased 96.7471 million Yuan on a y-o-y basis with growth rate of -95.54%
mainly because at same period last year received a consideration for reorganization of Shyndec Pharmaceutical while no such item
in the period;
30. Subtotal of cash in-flow from investing activities: decreased 150 million Yuan on a y-o-y basis with growth rate of -63.14%
mainly because the investment dividend received from joint venture declined on a y-o-y basis; and at same period last year received
a consideration for reorganization of Shyndec Pharmaceutical while no such item in the period;
31. Net cash paid from disposal of subsidiaries and other business units: increased 5.328 million Yuan on a y-o-y basis mainly due to
the investment amount for new company acquisition in the period while no such item at same period last year;
32. Cash payments related to other investing activities: decreased 78.3182 million Yuan on a y-o-y basis with growth rate of -97.99%
mainly because at same period last year the entrusted loans of Sinopharm Zhijun (Suzhou) was paid while no such item in the
period;
33. Net cash flows from investing activities: decreased 84.2184 million Yuan on a y-o-y basis with growth rate of -102.33% mainly
because the investment dividend received from joint venture declined on a y-o-y basis; and at same period last year received a
consideration for reorganization of Shyndec Pharmaceutical while no such item in the period;
34. Cash proceeds from investments by others: decreased 2744 million Yuan on a y-o-y basis with growth rate of -98.40% mainly
because at same period last year subsidiary Guoda Drugstore received a capital increased amount from strategy investor while no
such item in the period;
35. Cash received from borrowings: decreased 32.9702 million Yuan on a y-o-y basis with growth rate of -66.38% mainly because
the bank current loans in the period declined on a y-o-y basis;
36. Cash receipts related to other financing activities: decreased 107 million Yuan on a y-o-y basis with growth rate of -98.19%
mainly because at same period last year received a money order security while no such item in the period;
37. Sub-total of cash inflows from financing activities: decreased 2884 million Yuan on a y-o-y basis with growth rate of -97.86%
mainly because at same period last year subsidiary Guoda Drugstore received a capital increased amount from strategy investor
while no such item in the period;
38. Cash payments for distribution of dividends or profit and interest expenses: increased 174 million Yuan on a y-o-y basis with
growth rate of 62.86% mainly because the interest of supply chain financing increased on a y-o-y basis in the period;
39. Cash payments related to other financing activities: increased 544 million Yuan on a y-o-y basis with growth rate of 896.87%
mainly due to the implementation of new leasing standards in the period the rents paid in the period are reckoned into cash paid with
other financing activity concerned while no such item at same period lat year;
40. Sub-total of cash outflows from financing activities: increased 712 million Yuan on a y-o-y basis with growth rate of 170.65%
mainly due to the implementation of new leasing standards in the period the rents paid in the period are reckoned into cash paid with
other financing activity concerned and the interest of supply chain financing increased on a y-o-y basis in the period;
41. Net cash flows from financing activities: decreased 3596 million Yuan on a y-o-y basis with growth rate of -142.10% mainly
because at same period last year subsidiary Guoda Drugstore received a capital increased amount from strategy investor while no
such item in the period;
42. Eefect of foreign exchange rate changes on cash and cash equivalents: increased 138500 Yuan on a y-o-y basis with growth rate
of 44.04% mainly due to the impact of exchange rate changes;
43. Net increase incash and cash equivalents: decreased 3171 million Yuan on a y-o-y basis with growth rate of -105.28% mainly
because at same period last year subsidiary Guoda Drugstore received a capital increased amount from strategy investor while no
such item in the period;
44. Cash and cash equivalents at beginning of the year: increased 3959 million Yuan on a y-o-y basis with growth rate of 107.76%
mainly because at second half of last year subsidiary Guoda Drugstore received a capital increased amount from strategy investor
while no such item at period-begin of last year.II. Progress and influence of the main events as well as solution analysis specification
□Applicable √ Not applicable
Progress of shares buy-back
□Applicable √Not applicable
Implementation progress of the reduction of repurchases shares by centralized bidding
□Applicable √Not applicable
III. Commitments that the company shareholders actual controller offeror directors
supervisors senior management or other related parties have fulfilled during the reporting
period and have not yet fulfilled by the end of reporting period
□Applicable √ Not applicable
There are no commitments that the company shareholders actual controller offeror directors supervisors senior management or
other related parties have fulfilled during the reporting period and have not yet fulfilled by the end of reporting period.IV. Particular about security investment
□Applicable √ Not applicable
The Company had no security investment in Period.V. Trust financing
□Applicable √ Not applicable
The Company had no trust financing in Period.VI. Particulars about derivatives investment
□Applicable √ Not applicable
The Company had no derivatives investment in Period.VII. Registration form of receiving research communication and interview in the report
period
□Applicable √ Not applicable
The Company has no research communication and interview accepted in the Period.VIII. Guarantee outside against the regulation
□Applicable √Not applicable
The Company had no guarantee outside against the regulation in the reporting period.IX. Non-operational fund occupation from controlling shareholders and its related party
□Applicable √ Not applicable
The Company had no non-operational fund occupation from controlling shareholders and its related party.Section IV. Financial Statement
I. Financial statement
1. Consolidate balance sheet
Prepared by China National Accord Medicines Corporation Ltd.
2019-09-30
In RMB
Item 2019-9-30 2018-12-31
Current assets:
Monetary funds 7810810868.51 8089781304.56
Settlement provisions
Capital lent
Tradable financial assets
Financial assets measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial assets
Note receivable 585211751.81 1357311929.63
Account receivable 13181036029.36 9336861647.92
Receivable financing 400387183.26
Advances to suppliers 424448767.10 583484515.95
Insurance receivable
Reinsurance receivables
Contract reserve of reinsurance
receivable
Other receivables 522497740.14 643493359.32
Including: Interest receivable 14401063.47 8223327.64
Dividend receivable
Buying back the sale of financial
assets
Inventories 5274930261.55 4389335942.19
Contractual assets
Assets held for sale
Non-current asset due within one
year
Other current assets 69262261.99 95347629.18
Total current assets 28268584863.72 24495616328.75
Non-current assets:
Loans and payments on behalf
Debt investment
Finance asset available for sales
Other debt investment
Held-to-maturity investment
Long-term account receivable
Long-term equity investment 2107690039.44 1880393786.10
Other equity instruments
investment
13685760.00 13685760.00
Other non-current financial assets 140000000.00 140000000.00
Investment properties 139672194.89 144894495.97
Fixed assets 583995191.53 607933827.67
Construction in progress 35681041.39 36412614.61
Productive biological asset
Oil and gas asset
Right-of-use assets 1860064348.67
Intangible assets 314251903.10 319207126.15
Expense on Research and
Development
Goodwill 871041800.60 833547800.60
Long-term prepaid expenses 330156094.79 311328706.46
Deferred tax assets 78340768.87 74914209.95
Other non-current asset 73829180.67 72365863.71
Total non-current asset 6548408323.95 4434684191.22
Total assets 34816993187.67 28930300519.97
Current liabilities:
Short-term borrowings 2417214478.23 2597652702.43
Loan from central bank
Capital borrowed
Transactional financial liability
Financial liability measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial liability
Note payable 4087524569.31 3416755681.80
Account payable 9146870315.29 6468535961.17
Accounts received in advance
Contractual liability 226493600.53 255590612.37
Selling financial asset of
repurchase
Absorbing deposit and interbank
deposit
Security trading of agency
Security sales of agency
Employee benefits payable 208422163.84 231866407.40
Taxes payable 240761116.26 241980412.72
Other account payable 1639777109.48 1539436971.93
Incl: Interest payable 23295353.88 21906660.63
Dividend payable 11095744.80 6389320.96
Commission charge and
commission payable
Reinsurance payable
Liability held for sale
Non-current liabilities due within
one year
538837869.81 5861324.37
Other current liabilities 623159.83 292465.75
Total current liabilities 18506524382.58 14757972539.94
Non-current liabilities:
Insurance contract reserve
Long-term borrowings 31600000.00
Bonds payable
Including: Preferred stock
Perpetual capital
securities
Lease liability 1165308548.15
Long-term payable 800000.00 4563978.52
Long-term employee benefits
payable
1915000.00 2050000.00
Accrual liability
Deferred income 90111450.25 91491170.40
Deferred tax liabilities 66067559.30 67605161.88
Other non-current liabilities 68388290.57 69241176.18
Total non-current liabilities 1392590848.27 266551486.98
Total liabilities 19899115230.85 15024524026.92
Owner’s equity:
Share capital 428126983.00 428126983.00
Other equity instrument
Including: Preferred stock
Perpetual capital
securities
Capital surplus 4363409728.51 4320984981.51
Less: Inventory shares
Other comprehensive income
Reasonable reserve
Surplus reserve 214063491.50 214063491.50
Provision of general risk
Retained earnings 7446150420.99 6655257147.27
Shareholders’ equity attributable to
shareholders of the parent
12451750624.00 11618432603.28
Non-controlling interests 2466127332.82 2287343889.77
Total shareholders’ equity 14917877956.82 13905776493.05
Total liabilities and shareholders’ equity 34816993187.67 28930300519.97
Legal representative: Lin Zhaoxiong
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Wang Ying
2. Balance Sheet of Parent Company
In RMB
Item 2019-9-30 2018-12-31
Current assets:
Cash and bank balances 2544212671.60 1817654598.01
Tradable financial assets
Financial assets measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial assets
Note receivable 33503980.32 63870980.39
Account receivable 759614729.17 631236593.94
Receivable financing 16673997.31
Advances to suppliers 3026025.81 4760182.00
Other receivable 1866735563.06 1541980883.50
Including: Interest receivable 16497156.40 7550877.07
Dividend receivable
Inventories 211858298.59 158166185.65
Contractual assets
Assets held for sale
Non-current assets maturing within
one year
Other current assets 39482.38 39482.38
Total current assets 5435664748.24 4217708905.87
Non-current assets:
Debt investment
Available-for-sale financial assets
Other debt investment
Held-to-maturity investments
Long-term receivables
Long-term equity investments 7693092094.23 7432906692.24
Investment in other equity
instrument
Other non-current financial assets 140000000.00 140000000.00
Investment properties 1560072.33 1955854.46
Fixed assets 15474034.96 21362422.03
Construction in progress
Productive biological assets
Oil and natural gas assets
Right-of-use assets 6500265.79
Intangible assets 2783945.44 2452222.51
Research and development costs
Goodwill
Long-term deferred expenses 6527719.68 7481809.53
Deferred income tax assets
Other non-current assets 7000000.00 7000000.00
Total non-current assets 7872938132.43 7613159000.77
Total assets 13308602880.67 11830867906.64
Current liabilities:
Short-term borrowings 280000000.00 539000000.00
Transactional financial liability
Financial liability measured by fair
value and with variation reckoned into
current gains/losses
Derivative financial liability
Notes payable 390519916.75 252317800.78
Account payable 630198511.72 442049241.22
Accounts received in advance
Contractual liability 1694562.86 4182083.40
Employee benefits payable 37876995.85 36233563.12
Taxes payable 9336735.58 13426601.90
Other payable 1894492989.75 1481817856.56
Incl: Interest payable 8063589.67 1354592.35
Dividends payable
Liability held for sale
Non-current liabilities due within
one year
32573100.20
Other current liabilities 292740.68 226427.99
Total current liabilities 3276985553.39 2769253574.97
Non-current liabilities:
Long-term borrowings 31600000.00
Bonds payable
Including: preferred stock
Perpetual capital
securities
Lease liabilities 5715312.04
Long-term payables 800000.00 800000.00
Long-term employee benefits
payable
102000.00 118000.00
Accrued liabilities
Deferred income 1388958.78 1687899.50
Deferred tax liabilities 1644875.80 2298426.39
Other non-current liabilities
Total non-current liabilities 9651146.62 36504325.89
Total liabilities 3286636700.01 2805757900.86
Owners’ equity:
Share capital 428126983.00 428126983.00
Other equity instrument
Including: preferred stock
Perpetual capital
securities
Capital surplus 4468787524.26 4426362777.26
Less: Inventory shares
Other comprehensive income
Special reserve
Surplus reserve 214063491.50 214063491.50
Retained earnings 4910988181.90 3956556754.02
Total shareholders’ equity 10021966180.66 9025110005.78
Total liabilities and shareholders’ equity 13308602880.67 11830867906.64
3. Consolidated Profit Statement (the period)
In RMB
Item Current Period Last Period
I. Total operating revenue 13647793431.64 10987540368.77
Including: Operating revenue 13647793431.64 10987540368.77
Interest revenue
Insurance gained
Commission charge and
commission revenue
II. Total operating costs 13305315433.53 10672195431.17
Including: Operating costs 12253508326.76 9749853630.20
Interest expense
Commission charge and
commission expense
Cash surrender value
Net amount of expense of
compensation
Net amount of withdrawal of
insurance contract reserve
Bonus expense of guarantee slip
Reinsurance expense
Tax and surcharges 36513174.49 30175966.21
Selling expense 763231928.31 682736449.56
Administrative expense 208311402.38 188693332.32
R&D expense
Finance costs 43750601.59 20736052.88
Incl: Interest cost 86528994.84 45676535.07
Interest income 42778570.08 26253068.71
Add: other income 12116753.12 1815373.95
Investment income (Loss is
listed with “-”)
86069936.49 78983284.46
Incl: Investment income from
associates
86019936.49 78933284.46
The termination of income
recognition for financial assets measured
by amortized cost(Loss is listed with “-”)
Exchange income (Loss is
listed with “-”)
Net exposure hedging income
(Loss is listed with “-”)
Income from change of fair
value (Loss is listed with “-”)
Impairment losses on financial
assets (Loss is listed with “-”)
-3211918.65 -547491.37
Impairment losses (Loss is
listed with “-”)
-705879.81 392308.58
Gain on disposal of assets
(Loss is listed with “-”)
613909.71 76479.50
III. Operating profit (Loss is listed with 437360798.97 396064892.72
“-”)
Add: Non-operating income 3202332.16 1553611.12
Less: Non-operating expense 638789.06 374027.37
IV. Total profit (Loss is listed with “-”) 439924342.07 397244476.47
Less: Income taxes 80632027.90 76038019.79
V. Net profit (Net loss is listed with “-”) 359292314.17 321206456.68
(i) Classify by business continuity
1. Net Profit from continuingoperations (net loss listed with ‘-”)
359292314.17 321206456.68
2.termination of net profit (net losslisted with ‘-”)
(ii) Attributable to
1. Owners of the parent 311310706.52 285244535.54
2. Non-controlling interests 47981607.65 35961921.14
VI. Net after-tax of other comprehensive
income
Net after-tax of other comprehensive
income attributable to owners of parent
company
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1.Changes of the defined
benefit plans that re-measured
2.Other comprehensive
income under equity method that cannot
be transfer to gain/loss
3.Change of fair value of
investment in other equity instrument
4.Fair value change of
enterprise's credit risk
5. Other
(ii) Other comprehensive income
items which will be reclassified
subsequently to profit or loss
1.Other comprehensive
income under equity method that can
transfer to gain/loss
2.Change of fair value of
other debt investment
3.gain/loss of fair value
changes for available-for-sale financial
assets
4.Amount of financial assets
re-classify to other comprehensive
income
5.Gain/loss of
held-to-maturity investments that
re-classify to available-for-sale financial
asset
6.Credit impairment
provision for other debt investment
7.Cash flow hedging reserve
8.Translation differences
arising on translation of foreign currency
financial statements
9.Other
Net after-tax of other comprehensive
income attributable to minority
shareholders
VII. Total comprehensive income 359292314.17 321206456.68
Total comprehensive income for the
yearattributable to shareholders of the
parent
311310706.52 285244535.54
Total comprehensive income for the
year attributable tonon-controlling
interests
47981607.65 35961921.14
VIII. Earnings per share:
(i) Basic earnings per share 0.735 0.666
(ii) Diluted earnings per share 0.735 0.666
As for the business merger under the same control in the Period 0 Yuan net profit realized before merger by the
combined party the net profit for combined party in last period was 0 Yuan.Legal representative: Lin Zhaoxiong
Person in charge of accounting works: Wei Pingxiao
Person in charge of accounting institution: Wang Ying
4. Profit Statement of Parent Company (the period)
In RMB
Item Current Period Last Period
I. Operating revenue 1112624846.96 899859002.45
Less: Operating costs 1064701021.03 856296603.88
Tax and surcharge 1964184.59 1445734.44
Selling expenses 17984619.36 16953141.79
Administrative expenses 24299300.83 16785749.55
R&D expenses
Financial costs -11487202.76 -10270272.65
Incl: Interest expense 15442321.41 10951050.33
Incl: Interest income 27695670.05 21345942.02
Add: other income 219828.06 121990.82
Investment income (Loss is
listed with “-”)
473512554.91 84991405.06
Incl: Investment income from
associates
91259842.03 84991405.06
The termination of
income recognition for financial assets
measured by amortized cost (Loss is
listed with “-”)
Net exposure hedging income
(Loss is listed with “-”)
Changing income of fair
value (Loss is listed with “-”)
Impairment losses on
financial assets (Loss is listed with “-”)
-161522.25
Impairment loss (Loss is
listed with “-”)
-234019.78 152059.06
Gain on disposal of assets
(Loss is listed with “-”)
181433.34 11116.50
II. Operating profits (Loss is listed with
“-”)
488681198.19 103924616.88
Add: Non-operating income 373.35 3.98
Less: Non-operating expense
III. Total Profit (Loss is listed with “-”) 488681571.54 103924620.86
Less: Income taxes 3675740.93 4806491.84
IV. Net profit (Net loss is listed with
“-”)
485005830.61 99118129.02
(i) Net Profit from continuingoperations (net loss listed with ‘-”)
485005830.61 99118129.02
(ii) termination of net profit (netloss listed with ‘-”)
V. Net after-tax of other comprehensive
income
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1.Changes of the defined
benefit plans that re-measured
2.Other comprehensive
income under equity method that cannot
be transfer to gain/loss
3.Change of fair value of
investment in other equity instrument
4.Fair value change of
enterprise's credit risk
5. Other
(II) Other comprehensive income
items which will be reclassified
subsequently to profit or loss
1.Other comprehensive
income under equity method that can
transfer to gain/loss
2.Change of fair value of
other debt investment
3.gain/loss of fair value
changes for available-for-sale financial
assets
4.Amount of financial
assets re-classify to other
comprehensive income
5.Gain/loss of
held-to-maturity investments that
re-classify to available-for-sale financial
asset
6.Credit impairment
provision for other debt investment
7.Cash flow hedging
reserve
8.Translation differences
arising on translation of foreign
currency financial statements
9.Other
VI. Total comprehensive income 485005830.61 99118129.02
VII. Earnings per share:
(i) Basic earnings per share
(ii) Diluted earnings per share
5. Consolidated Profit Statement (form the year-begin to the period-end)
In RMB
Item Current Period Last Period
I. Total operating revenue 38875940809.07 31766707068.44
Including: Operating revenue 38875940809.07 31766707068.44
Interest revenue
Insurance gained
Commission charge and
commission revenue
II. Total operating cost 37747619061.94 30779410046.43
Including: Operating costs 34669028279.63 28117497354.04
Interest expense
Commission charge and
commission expense
Cash surrender value
Net amount of expense of
compensation
Net amount of withdrawal of
insurance contract reserve
Bonus expense of guarantee slip
Reinsurance expense
Tax and surcharges 98652400.93 86796493.46
Salling expenses 2246564429.04 1956325205.63
Administrative expenses 585528096.51 540513396.10
R&D expense
Finance costs 147845855.83 78277597.20
Incl: Interest cost 256058467.21 129032902.25
Interest income 103408606.99 49335302.27
Add: other incomes 27107672.14 12404586.52
Investment income (Loss is
listed with “-”)
255212226.48 241677055.81
Incl: Investment income from
associates
255162226.48 241595555.81
The termination of income
recognition for financial assets measured
by amortized cost(Loss is listed with “-”)
Exchange income (Loss is
listed with “-”)
Net exposure hedging income
(Loss is listed with “-”)
Income from change of fair
value (Loss is listed with “-”)
Impairment losses on financial
assets (Loss is listed with “-”)
-14646019.78 479210.87
Impairment losses (Loss is
listed with “-”)
-831434.15 -116540.68
Gain on disposal of assets
(Loss is listed with “-”)
584184.27 4357644.11
III. Operating profit (Loss is listed with
“-”)
1395748376.09 1246098978.64
Add: Non-operating income 6869502.41 7052562.23
Less: Non-operating expense 2357054.62 2171320.17
IV. Total profit (Loss is listed with “-”) 1400260823.88 1250980220.70
Less: Income taxes 272875954.40 240524754.11
V. Net profit (Net loss is listed with “-”) 1127384869.48 1010455466.59
(i) Classify by business continuity
1. Net Profit from continuingoperations (net loss listed with ‘-”)
1127384869.48 1010455466.59
2.termination of net profit (net losslisted with ‘-”)
(ii) Classify by ownership
1. Owners of the parent 962144066.92 926971570.47
2. Non-controlling interests 165240802.56 83483896.12
VI. Net after-tax of other comprehensive
income
Net after-tax of other comprehensive
income attributable to owners of parent
company
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1.Changes of the defined
benefit plans that re-measured
2.Other comprehensive
income under equity method that cannot
be transfer to gain/loss
3.Change of fair value of
investment in other equity instrument
4.Fair value change of
enterprise's credit risk
5. Other
(ii) Other comprehensive income
items which will be reclassified
subsequently to profit or loss
1.Other comprehensive
income under equity method that can
transfer to gain/loss
2.Change of fair value of
other debt investment
3.gain/loss of fair value
changes for available-for-sale financial
assets
4.Amount of financial assets
re-classify to other comprehensive
income
5.Gain/loss of
held-to-maturity investments that
re-classify to available-for-sale financial
asset
6.Credit impairment
provision for other debt investment
7.Cash flow hedging reserve
8.Translation differences
arising on translation of foreign currency
financial statements
9.Other
Net after-tax of other comprehensive
income attributable to minority
shareholders
VII. Total comprehensive income 1127384869.48 1010455466.59
Total comprehensive income for the
yearattributable to shareholders of the
parent
962144066.92 926971570.47
Total comprehensive income for the
year attributable tonon-controlling
interests
165240802.56 83483896.12
VIII. Earnings per share:
(i) Basic earnings per share 2.247 2.165
(ii) Diluted earnings per share 2.247 2.165
As for the business merger under the same control in the Period 0 Yuan net profit realized before merger by the
combined party the net profit for combined party in last period was 0 Yuan.
6. Profit Statement of Parent Company (form the year-begin to the period-end)
In RMB
Item Current Period Last Period
I. Operating revenue 3120629410.26 2587480358.28
Less: Operating costs 2985973415.79 2471014077.79
Taxes and surcharge 4483432.58 3462103.37
Selling expenses 49036664.17 42847937.24
Administrative expenses 62356107.14 50464856.30
R&D expenses
Finance costs -39885446.76 -29640152.73
Incl: Interest expense 38713629.13 31721163.76
Incl: Interest income 80175392.47 62271142.76
Add: other income 552592.19 1421335.96
Investment income (Loss is
listed with “-”)
1081800975.38 619832149.52
Incl: Investment income from
associates
272540375.14 258317695.20
The termination of
income recognition for financial assets
measured by amortized cost (Loss is
listed with “-”)
Net exposure hedging income
(Loss is listed with “-”)
Changing income of fair
value (Loss is listed with “-”)
Impairment losses on
financial assets (Loss is listed with “-”)
-2527287.33 7411.02
Impairment loss (Loss is
listed with “-”)
-336132.62 -478894.27
Gain on disposal of assets
(Loss is listed with “-”)
155358.82 11116.50
II. Operating profit (Loss is listed with
“-”)
1138310743.78 670124655.04
Add: Non-operating income 46442.75 37.06
Less: Non-operating expenses 127688.63
III. Total Profit (Loss is listed with “-”) 1138357186.53 669997003.47
Less: Income taxes 12674965.45 11099365.68
IV. Net profit (Net loss is listed with
“-”)
1125682221.08 658897637.79
(i) Net Profit from continuingoperations (net loss listed with ‘-”)
1125682221.08 658897637.79
(ii) termination of net profit (netloss listed with ‘-”)
V. Net after-tax of other comprehensive
income
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1.Changes of the defined
benefit plans that re-measured
2.Other comprehensive
income under equity method that cannot
be transfer to gain/loss
3.Change of fair value of
investment in other equity instrument
4.Fair value change of
enterprise's credit risk
5. Other
(II) Other comprehensive income
items which will be reclassified
subsequently to profit or loss
1.Other comprehensive
income under equity method that can
transfer to gain/loss
2.Change of fair value of
other debt investment
3.gain/loss of fair value
changes for available-for-sale financial
assets
4.Amount of financial
assets re-classify to other
comprehensive income
5.Gain/loss of
held-to-maturity investments that
re-classify to available-for-sale financial
asset
6.Credit impairment
provision for other debt investment
7.Cash flow hedging
reserve
8.Translation differences
arising on translation of foreign
currency financial statements
9.Other
VI. Total comprehensive income 1125682221.08 658897637.79
VII. Earnings per share:
(i) Basic earnings per share
(ii) Diluted earnings per share
7. Consolidated Cash Flow Statement (form the year-begin to the period-end)
In RMB
Item Current Period Last Period
I. Cash flows arising from operating
activities:
Cash received from sales of good
or rendering of services
39464106244.18 33576126717.79
Net increase of customer deposit
and interbank deposit
Net increase of loan from central
bank
Net increase of capital borrowed
from other financial institution
Cash received from original
insurance contract fee
Net cash received from reinsurance
business
Net increase of insured savings
and investment
Cash received from interest
commission charge and commission
Net increase of capital borrowed
Net increase of returned business
capital
Net cash received by agents in sale
and purchase of securities
Tax refunds 3508074.72 1714760.21
Cash receipts related to other
operating activities
497412494.23 503409429.80
Sub-total of cash inflows from
operating activities
39965026813.13 34081250907.80
Cash paid for goods and services 35594093946.44 30058268141.08
Net increase of customer loans and
advances
Net increase of deposits in central
bank and interbank
Cash paid for original insurance
contract compensation
Net increase of capital lent
Cash paid for interest commission
charge and commission
Cash paid for bonus of guarantee
slip
Cash paid to and on behalf of
employees
1592033194.68 1392220211.12
Cash paid for all types of taxes 941789797.45 818864295.31
Cash payments related to other
operating activities
764147713.34 1247906964.93
Sub-total of cash outflows from
operating activities
38892064651.91 33517259612.44
Net cash flows from operating activities 1072962161.22 563991295.36
II. Cash flows arising from investing
activities:
Cash received from recovering
investment
Cash received from returns on
investments
78242963.78 130963345.37
Net cash received from disposal of
fixed intangible assets and other
long-term assets
4967658.92 5751674.16
Net cash received from disposal of
subsidiaries and other units
Cash receipts related to other
investing activities
4514498.90 101261607.73
Sub-total of cash inflows from investing
activities
87725121.60 237976627.26
Cash paid for acquisition of fixed
assets intangible assetsand other
long-term assets
162770914.81 150353192.93
Cash paid for acquisition of
investments
84539317.61 90000000.00
Net increase of mortgaged loans
Net cash paid from disposal of
subsidiaries and otherbusiness units
5328000.00
Cash payments related to other
investing activities
1603306.28 79921476.82
Sub-total of cash outflows from
investing activities activities
254241538.70 320274669.75
Net cash flows arising from investing
activities
-166516417.10 -82298042.49
III. Cash flows arising from financing
activities
Cash proceeds from investments
by others
44548000.00 2788851200.00
Incl: Cash proceeds from
subsidiary investments by
non-controlling shareholders
44548000.00 2788851200.00
Cash received from borrowings 16700000.00 49670200.30
Cash receipts related to other
financing activities
1967629.61 108949307.54
Subtotal of cash inflow from financing
activities
63215629.61 2947470707.84
Cash repayments for debts 73307142.79 79670200.30
Cash payments for distribution of
dividends or profit andinterest expenses
450504620.79 276628059.98
Incl: Profit and dividends paid to
non-controllingshareholders of
subsidiaries
28493123.11 56858945.30
Cash payments related to other
financing activities s
604680365.03 60658096.82
Subtotal of cash outflow from financing
activities
1128492128.61 416956357.10
Net cash flows from financing activities -1065276499.00 2530514350.74
IV.Effect of foreign exchange rate
changes on cash and cash equivalents
Influence on cash and cash equivalents
due to fluctuation in exchange rate
-175994.42 -314517.97
V. Net increasein cash and cash
equivalents
-159006749.30 3011893085.64
Add: Cash and cash equivalents at
beginning of the year
7632117020.77 3673498691.48
VI. Cash and cash equivalents at end of
year
7473110271.47 6685391777.12
8. Cash Flow Statement of Parent Company (form the year-begin to the period-end)
In RMB
Item Current Period Last Period
I. Cash flows arising from operating
activities:
Cash received from sales of good
or rendering of services
3217890947.38 2681236630.70
Write-back of tax received
Cash receipts related to other
operating activities
32674054.58 91958196.80
Sub-total of cash inflows from
operating activities
3250565001.96 2773194827.50
Cash paid for goods and services 3191926190.64 2559377589.52
Cash paid to and on behalf of
employees
73601798.69 61913310.95
Cash paid for all types of taxes 43156828.71 29801808.96
Cash payments related to other
operating activities
24724274.57 45140599.54
Subtotal of cash outflow from operating
activities
3333409092.61 2696233308.97
Net cash flows arising from operating
activities
-82844090.65 76961518.53
II. Cash flows arising from investing
activities:
Cash received from recovering
investment
Cash received from returns of
investments
619976538.54 255904643.39
Net cash received from disposal of
fixed assets intangible assets and other
long-term assets
3961383.00 35200.00
Net cash received from disposal of
subsidiaries and other units
Cash receipts related to other
investing activities
1482390000.00 1218035586.01
Subtotal of cash inflow from investing
activities
2106327921.54 1473975429.40
Cash paid for acquisition of fixed
assets intangible assets andother
long-term assets
6777035.03 8607026.77
Cash paid for investment 19998000.00 90000000.00
Net cash received from
subsidiaries and other units obtained
Cash payments related to other
investing activities
1812850181.28 1267321606.82
Subtotal of cash outflow from investing
activities
1839625216.31 1365928633.59
Net cash flows from investing activities
activities
266702705.23 108046795.81
III. Cash flows arising from financing
activities:
Cash received from absorbing
investment
Cash received from borrowings 10000000.00 10000000.00
Cash receipts related to other
financing activities
18437509464.22 12559913378.52
Subtotal of cash inflow from financing
activities
18447509464.22 12569913378.52
Cash repayments for debts 10000000.00 10000000.00
Cash payments for distribution of
dividends profit or interestexpenses
191576803.94 153116428.79
Cash payments related to other
financing activities
17703057206.85 12723602657.57
Subtotal of cash outflow from financing
activities
17904634010.79 12886719086.36
Net cash flows from financing activities 542875453.43 -316805707.84
IV. .Effect of foreign exchange rate
changes on cash and cash equivalents
-175994.42 -314517.97
V. Net increase in cash and cash
equivalents
726558073.59 -132111911.47
Add: Cash and cash equivalents at
beginning of the year
1817654598.01 1776696342.87
VI. Cash and cash equivalents at end of
year
2544212671.60 1644584431.40
II. Financial statement adjustment
1. Relevant items of the financial statement at beginning of the year when implementing the new financial
instrument standards new revenue standards or new leasing standards since 2019
√ Applicable □ Not applicable
Consolidated Balance Sheet
In RMB
Item 2018-12-31 2019-01-01 Adjustment
Current assets:
Monetary funds 8089781304.56 8089781304.56
Settlement provisions
Capital lent
Tradable financial assets
Financial assets
measured by fair value and
with variation reckoned into
current gains/losses
Derivative financial
assets
Note receivable 1357311929.63 789536654.23 -567775275.40
Account receivable 9336861647.92 9336861647.92
Receivable financing 567775275.40 567775275.40
Advances to suppliers 583484515.95 419443944.83 -164040571.12
Insurance receivable
Reinsurance receivables
Contract reserve of
reinsurance receivable
Other receivables 643493359.32 643493359.32
Including: Interest
receivable
8223327.64 8223327.64
Dividend
receivable
Buying back the sale of
financial assets
Inventories 4389335942.19 4389335942.19
Contractual assets
Assets held for sale
Non-current asset due
within one year
Other current assets 95347629.18 95347629.18
Total current assets 24495616328.75 24331575757.63 -164040571.12
Non-current assets:
Loans and payments on
behalf
Debt investment
Finance asset available
for sales
Other debt investment
Held-to-maturity
investment
Long-term account
receivable
Long-term equity
investment
1880393786.10 1880393786.10
Other equity instruments
investment
13685760.00 13685760.00
Other non-current
financial assets
140000000.00 140000000.00
Investment properties 144894495.97 144894495.97
Fixed assets 607933827.67 594067973.91 -13865853.76
Construction in progress 36412614.61 36412614.61
Productive biological
asset
Oil and gas asset
Right-of-use assets 1782725159.78 1782725159.78
Intangible assets 319207126.15 318693082.72 -514043.43
Expense on Research
and Development
Goodwill 833547800.60 833547800.60
Long-term prepaid
expenses
311328706.46 311328706.46
Deferred tax assets 74914209.95 74914209.95
Other non-current asset 72365863.71 58168919.11 -14196944.60
Total non-current asset 4434684191.22 6188832509.21 1754148317.99
Total assets 28930300519.97 30520408266.84 1590107746.87
Current liabilities:
Short-term borrowings 2597652702.43 2597652702.43
Loan from central bank
Capital borrowed
Transactional financial
liability
Financial liability
measured by fair value and
with variation reckoned into
current gains/losses
Derivative financial
liability
Note payable 3416755681.80 3416755681.80
Account payable 6468535961.17 6468535961.17
Accounts received in
advance
Contractual liability 255590612.37 255590612.37
Selling financial asset of
repurchase
Absorbing deposit and
interbank deposit
Security trading of
agency
Security sales of agency
Employee benefits
payable
231866407.40 231866407.40
Taxes payable 241980412.72 241980412.72
Other account payable 1539436971.93 1539436971.93
Incl: Interest payable 21906660.63 21906660.63
Dividend
payable
6389320.96 6389320.96
Commission charge and
commission payable
Reinsurance payable
Liability held for sale
Non-current liabilities
due within one year
5861324.37 495132751.96 489271427.59
Other current liabilities 292465.75 292465.75
Total current liabilities 14757972539.94 15247243967.53 489271427.59
Non-current liabilities:
Insurance contract reserve
Long-term borrowings 31600000.00 31600000.00
Bonds payable
Including: Preferred
stock
Perpetual
capital securities
Lease liability 1104600297.80 1104600297.80
Long-term payable 4563978.52 800000.00 -3763978.52
Long-term employee
benefits payable
2050000.00 2050000.00
Accrual liability
Deferred income 91491170.40 91491170.40
Deferred tax liabilities 67605161.88 67605161.88
Other non-current
liabilities
69241176.18 69241176.18
Total non-current liabilities 266551486.98 1367387806.26 1100836319.28
Total liabilities 15024524026.92 16614631773.79 1590107746.87
Owner’s equity:
Share capital 428126983.00 428126983.00
Other equity instrument
Including: Preferred
stock
Perpetual
capital securities
Capital surplus 4320984981.51 4320984981.51
Less: Inventory shares
Other comprehensive
income
Reasonable reserve
Surplus reserve 214063491.50 214063491.50
Provision of general risk
Retained earnings 6655257147.27 6655257147.27
Shareholders’ equity
attributable to shareholders
of the parent
11618432603.28 11618432603.28
Non-controlling 2287343889.77 2287343889.77
interests
Total shareholders’ equity 13905776493.05 13905776493.05
Total liabilities and
shareholders’ equity
28930300519.97 30520408266.84 1590107746.87
Statement of adjustment
Balance Sheet of Parent Company
In RMB
Item 2018-12-31 2019-01-01 Adjustment
Current assets:
Cash and bank balances 1817654598.01 1817654598.01
Tradable financial assets
Financial assets
measured by fair value and
with variation reckoned into
current gains/losses
Derivative financial
assets
Note receivable 63870980.39 34154774.75 -29716205.64
Account receivable 631236593.94 631236593.94
Receivable financing 29716205.64 29716205.64
Advances to suppliers 4760182.00 4757318.66 -2863.34
Other receivable 1541980883.50 1541980883.50
Including: Interest
receivable
7550877.07 7550877.07
Dividend
receivable
Inventories 158166185.65 158166185.65
Contractual assets
Assets held for sale
Non-current assets
maturing within one year
Other current assets 39482.38 39482.38
Total current assets 4217708905.87 4217706042.53 -2863.34
Non-current assets:
Debt investment
Available-for-sale
financial assets
Other debt investment
Held-to-maturity
investments
Long-term receivables
Long-term equity
investments
7432906692.24 7432906692.24
Investment in other
equity instrument
Other non-current
financial assets
140000000.00 140000000.00
Investment properties 1955854.46 1955854.46
Fixed assets 21362422.03 21362422.03
Construction in progress
Productive biological
assets
Oil and natural gas
assets
Right-of-use assets 6827171.38 6827171.38
Intangible assets 2452222.51 2452222.51
Research and
development costs
Goodwill
Long-term deferred
expenses
7481809.53 7481809.53
Deferred income tax
assets
Other non-current assets 7000000.00 7000000.00
Total non-current assets 7613159000.77 7619986172.15 6827171.38
Total assets 11830867906.64 11837692214.68 6824308.04
Current liabilities:
Short-term borrowings 539000000.00 539000000.00
Transactional financial
liability
Financial liability
measured by fair value and
with variation reckoned into
current gains/losses
Derivative financial
liability
Notes payable 252317800.78 252317800.78
Account payable 442049241.22 442049241.22
Accounts received in
advance
Contractual liability 4182083.40 4182083.40
Employee benefits
payable
36233563.12 36233563.12
Taxes payable 13426601.90 13426601.90
Other payable 1481817856.56 1481817856.56
Incl: Interest payable 1354592.35 1354592.35
Dividends
payable
Liability held for sale
Non-current liabilities
due within one year
786068.44 786068.44
Other current liabilities 226427.99 226427.99
Total current liabilities 2769253574.97 2770039643.41 786068.44
Non-current liabilities:
Long-term borrowings 31600000.00 31600000.00
Bonds payable
Including: preferred
stock
Perpetual
capital securities
Lease liabilities 6038239.60 6038239.60
Long-term payables 800000.00 800000.00
Long-term employee
benefits payable
118000.00 118000.00
Accrued liabilities
Deferred income 1687899.50 1687899.50
Deferred tax liabilities 2298426.39 2298426.39
Other non-current
liabilities
Total non-current liabilities 36504325.89 42542565.49 6038239.60
Total liabilities 2805757900.86 2812582208.90 6824308.04
Owners’ equity:
Share capital 428126983.00 428126983.00
Other equity instrument
Including: preferred
stock
Perpetual
capital securities
Capital surplus 4426362777.26 4426362777.26
Less: Inventory shares
Other comprehensive
income
Special reserve
Surplus reserve 214063491.50 214063491.50
Retained earnings 3956556754.02 3956556754.02
Total shareholders’ equity 9025110005.78 9025110005.78
Total liabilities and
shareholders’ equity
11830867906.64 11837692214.68 6824308.04
Statement of adjustment
2. Explanation on comparative data in the early stage of retroactive adjustment while implemented the new
financial instrument standards or new leasing standards since 2019
□Applicable √ Not applicable
III. Audit report
Whether the 3rd quarterly report has been audited or not
□Yes √ No
The 3rd quarterly report of the Company has not been audited.
China National Accord Medicines Corporation Ltd.
Legal representative: Lin Zhaoxiong
24 October 2019
沪公网安备31011802005267号
